Antimicrobial agents in poorly accessible body compartments - Basics and clinics;Antibiotika im schwer erreichbaren kompartiment: Grundlagen und klinik

Chemotherapie Journal

Volumn 13, Issue 5, 2004, Pages 195-202

  Steiner, Ilka ^a,b   Müller, Markus ^a,b   Joukhadar, Christian ^a,b  

^a Allgemeines Krankenhaus ^*

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Antimicrobial agents; Pharmacokinetics; Poorly accessible body compartments

Indexed keywords

ANTIINFECTIVE AGENT;

CENTRAL NERVOUS SYSTEM; COMPARTMENT MODEL; CONCENTRATION RESPONSE; DRUG EFFICACY; ENCAPSULATION; EQUILIBRIUM CONSTANT; HUMAN; ISCHEMIA; MINIMUM INHIBITORY CONCENTRATION; PATHOGENESIS; REVIEW; TREATMENT OUTCOME;

EID: 7044231526     PISSN: 09406735     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. The management of neurosurgical patients with postoperative bacterial or aseptic meningitis or external ventricular drain-associated ventriculitis. Infection in Neurosurgery Working Party of the British Society for Antimicrobial Chemotherapy. Br J Neurosurg 2000;14:7-12.
2. Anstadt MP, Guill CK, Ferguson ER, Gordon HS, et al. Surgical versus nonsurgical treatment of empyema thoracis: an outcomes analysis. Am J Med Sci 2003;326:9-14.
3. Apelqvist J, Bakker K, van Houtum WH, Nabuurs-Franssen MH, et al. International consensus and practical guidelines on the management and the prevention of the diabetic foot. International Working Group on the Diabetic Foot. Diabetes Metab Res Rev 2000;16(suppl 1):S84-92.
4. Banh HL, Burton ME, Sperling MR. Interpatient and intrapatient variability in phenytoin protein binding. Ther Drug Monit 2002;24:379-85.
5. Bergogne-Berezin E. Antibiotic tissue concentrations revisited in lungs. Crit Care Med 2003;31:2242-3.
6. Boselli E, Allaouchiche B. Diffusion in bone tissue of antibiotics. Presse Med 1999;28:2265-76.
7. Breilh D, Saux MC, Maire P, Vergnaud JM, et al. Mixed pharmacokinetic population study and diffusion model to describe ciprofloxacin lung concentrations. Comput Biol Med 2001;31:147-55.
8. Brown EM, de Louvois J, Bayston R, Lees PD, et al. Distinguishing between chemical and bacterial meningitis in patients who have undergone neurosurgery. Clin Infect Dis 2002;34:556-8.
9. Brunner M, Reinprecht A, Illievich U, Spiss CK, et al. Penetration of fosfomycin into the parenchyma of human brain: a case study in three patients. Br J Clin Pharmacol 2002;54:548-50.
10. Charalambous CP, Zipitis CS, Kumar R, Lipsett PA, et al. Soft tissue infections of the extremities in an orthopaedic centre in the UK. J Infect. 2003;46:106-10.
11. Cruciani M, Gatti G, Lazzarini L, Furlan G, et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 1996;38:865-9.
12. Cruciani M, Navarra A, Di Perri G, Andreoni M, et al. Evaluation of intraventricular teicoplanin for the treatment of neurosurgical shunt infections. Clin Infect Dis 1992;15:285-9.
13. Dang CN, Prasad YD, Boulton AJ, Jude EB. Methicillin-resistant Staphylococcus aureus in the diabetic foot clinic: a worsening problem. Diabet Med 2003;20:159-61.
14. De Bels D, Korinek AM, Bismuth R, Trystram D, et al. Empirical treatment of adult postsurgical nosocomial meningitis. Acta Neurochir (Vienna) 2002;144:989-95.
15. Derendorf H, Gramatté T, Schäfer HG (Hrsg.). Pharmakokinetik - Einführung in die Theorie und Relevanz für die Arzneimitteltherapie. 2. Auflage. Stuttgart: Wissenschaftliche Verlagsgesellschaft, 2002.
16. Forgacs P, Geyer CA, Freidberg SR. Characterization of chemical meningitis after neurological surgery. Clin Infect Dis 2001;32:179-85.
17. Frossard M, Joukhadar C, Erovic BM, Dittrich P, et al. Distribution and antimicrobial activity of fosfomycin in the interstitial fluid of human soft tissues. Antimicrob Agents Chemother 2000;44:2728-32.
18. Fung HB, Chang JY, Kuczynski S. A practical guide to the treatment of complicated skin and soft tissue infections. Drugs 2003;63:1459-80.
19. Gerloff T. Impact of genetic polymorphisms in transmembrane carrier-systems on drug and xenobiotic distribution. Naunyn Schmiedebergs Arch Pharmacol 2003.
20. Gottlieb T, Atkins BL, Shaw DR. 7: Soft tissue, bone and joint infections. Med J Aust 2002;176:609-15.
21. Graziani AL, Lawson LA, Gibson GA, Steinberg MA, et al. Vancomycin concentrations in infected and noninfected human bone. Antimicrob Agents Chemother 1988;32:1320-2.
22. Hendrikse NH, de Vries EG, Eriks-Fluks L, van der Graaf WT, et al. A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier. Cancer Res 1999;59:2411-6.
23. Herkner H, Muller MR, Kreischitz N, Mayer BX, et al. Closed-chest microdialysis to measure antibiotic penetration into human lung tissue. Am J Respir Crit Care Med 2002;165:273-6.
24. Hillered L, Persson L. Microdialysis for neurochemical monitoring of the human brain. Scand Cardiovasc J 2003;37:13-7.
25. Incavo SJ, Ronchetti PJ, Choi JH, Wu H, et al. Penetration of piperacillin-tazobactam into cancellous and cortical bone tissues. Antimicrob Agents Chemother 1994;38:905-7.
26. Joseph TN, Chen AL, Di Cesare PE. Use of antibiotic-impregnated cement in total joint arthroplasty. J Am Acad Orthop Surg 2003;11:38-47.
27. Joukhadar C, Derendorf H, Muller M. Microdialysis. A novel tool for clinical studies of anti-infective agents. Eur J Clin Pharmacol 2001;57:211-9.
28. Joukhadar C, Frossard M, Mayer BX, Brunner M, et al. Impaired target site penetration of beta-lactams may account for therapeutic failure in patients with septic shock. Crit Care Med 2001;29:385-91.
29. Joukhadar C, Klein N, Frossard M, Minar E, et al. Angioplasty increases target site concentrations of ciprofloxacin in patients with peripheral arterial occlusive disease. Clin Pharmacol Ther 2001;70:532-9.
30. Joukhadar C, Stass H, Muller-Zellenberg U, Lackner E, et al. Penetration of moxifloxacin into healthy and inflamed subcutaneous adipose tissues in humans. Antimicrob Agents Chemother 2003;47:3099-103.
31. Klimas MT. Positron emission tomography and drug discovery: contributions to the understanding of pharmacokinetics, mechanism of action and disease state characterization. Mol Imaging Biol 2002;4:311-37.
32. Langer O, Mitterhauser M, Brunner M, Zeitlinger M, et al. Synthesis of fluorine-18-labeled ciprofloxacin for PET studies in humans. Nucl Med Biol 2003;30:285-91.
33. Laznicek M, Laznickova A. The effect of lipophilicity on the protein binding and blood cell uptake of some acidic drugs. J Pharm Biomed Anal 1995;13:823-8.
34. Legat FJ, Maier A, Dittrich P, Zenahlik P, et al. Penetration of fosfomycin into inflammatory lesions in patients with cellulitis or diabetic foot syndrome. Antimicrob Agents Chemother 2003;47:371-4.
35. Levison ME, Mallela S. Increasing antimicrobial resistance: therapeutic implications for enterococcal infections. Curr Infect Dis Rep 2000;2:417-23.
36. Levitt DG. PKQuest: capillary permeability limitation and plasma protein binding - application to human insulin, dicloxacillin and ceftriaxone pharmacokinetics. BMC Clin Pharmacol 2002;2:7.
37. Levy G. Impact of pharmacodynamic variability on drug delivery (1). Adv Drug Deliv Rev 1998;33:201-6.
38. Levy G. Predicting effective drug concentrations for individual patients. Determinants of pharmacodynamic variability. Clin Pharmacokinet 1998;34:323-33.
39. Lobati F, Herndon B, Bamberger D. Osteomyelitis: etiology, diagnosis, treatment and outcome in a public versus a private institution. Infection 2001;29:333-6.
40. Lonnroth P. Microdialysis - a new and promising method in clinical medicine. J Intern Med 1991;230:363-4.
41. Levering AM, Zhang J, Bannister GC, Lankester BJ, et al. Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. J Antimicrob Chemother 2002;50:73-7.
42. Lozier AP, Sciacca RR, Romagnoli MF, Connolly ES Jr. Ventriculostomy- related infections: a critical review of the literature. Neurosurgery 2002;51:170-81; discussion 181-2.
43. Melliere D, Berrahal D, D'Audiffret A, Desgranges P, et al. Percutaneous transluminal angioplasty in patients with ischemic tissue necrosis is worthwhile. Cardiovasc Surg 2001;9:122-6.
44. Muller M. Microdialysis in clinical drug delivery studies. Adv Drug Deliv Rev 2000;45:255-69.
45. Muller M. Science, medicine, and the future: microdialysis. BMJ 2002;324:588-91.
46. Muller M, Rohde B, Kovar A, Georgopoulos A, et al. Relationship between serum and free interstitial concentrations of cefodizime and cefpirome in muscle and subcutaneous adipose tissue of healthy volunteers measured by microdialysis. J Clin Pharmacol 1997;37:1108-13.
47. Nagl M, Neher C, Hager J, Pfausler B, et al. Bactericidal activity of vancomycin in cerebrospinal fluid. Antimicrob Agents Chemother 1999;43:1932-4.
48. Nau R, Sörgel F, Prange HW. Pharmacokinetic optimisation of the treatment of bacterial central nervous system infections. Clin Pharmacokinet 1998;35:223-46.
49. Parodi S, Lechner A, Osih R, Vespa P, et al. Nosocomial enterobacter meningitis: risk factors, management, and treatment outcomes. Clin Infect Dis 2003;37:159-66.
50. Periti P, Mazzei T, Mini E, Novelli A. Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part I). Clin Pharmacokinet 1989;16:193-214.
51. Pfausler B, Haring HP, Kampfl A, Wissel J, et al. Cerebrospinal fluid (CSF) pharmacokinetics of intraventricular vancomycin in patients with staphylococcal ventriculitis associated with external CSF drainage. Clin Infect Dis 1997;25:733-5.
52. Pfausler B, Spiss H, Beer R, Kampl A, et al. Treatment of staphylococcal ventriculitis associated with external cerebrospinal fluid drains: a prospective randomized trial of intravenous compared with intraventricular vancomycin therapy. J Neurosurg 2003;98:1040-4.
53. Pfausler B, Spiss H, Dittrich P, Zeitlinger M, et al. Concentrations of fosfomycin in the cerebrospinal fluid of neurointensive care patients with ventriculostomy-associated ventriculitis. J Antimicrob Chemother 2004;53:848-52.
54. Popick AC, Crouthamel WG, Bekersky I. Plasma protein binding of ceftriaxone. Xenobiotica 1987;17:1139-45.
55. Rowland M, Tozer TN. Clinical pharmacokinetics - concepts and applications. Third edition. Balimore Philadelphia: Williams & Wilkins, 1995.
56. Seppala H, Klaukka T, Vuopio-Varkila J, Muotiala A, et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N Engl J Med 1997;337:441-6.
57. Teixeira LR, Sasse SA, Villarino MA, Nguyen T, et al. Antibiotic levels in empyemic pleural fluid. Chest 2000;117:1734-9.
58. Thys JP, Vanderhoeft P, Herchuelz A, Bergmann P, et al. Penetration of aminoglycosides in uninfected pleural exudates and in pleural empyemas. Chest 1988;93:530-2.
59. Tomaselli F, Dittrich P, Maier A, Woltsche M, et al. Penetration of piperacillin and tazobactam into pneumonic human lung tissue measured by in vivo microdialysis. Br J Clin Pharmacol 2003;55:620-4.
60. Tomaselli F, Maier A, Smolle-Jüttner FM. Pharmakokinetik von Antibiotika im entzündeten und gesunden Lungengewebe. Wien Med Wochenschr 2003;153:342-4.
61. Uehlinger DE, Schaedeli F, Kinzig M, Sörgel F, et al. Pharmacokinetics of fleroxacin after multiple oral dosing in patients receiving regular hemodialysis. Antimicrob Agents Chemother 1996;40:1903-9.
62. Valko K, Nunhuck S, Bevan C, Abraham MH, et al. Fast gradient HPLC method to determine compounds binding to human serum albumin. Relationships with octanol/water and immobilized artificial membrane lipophilicity. J Pharm Sci 2003;92:2236-48.
63. Van Bambeke F, Balzi E, Tulkens PM. Antibiotic efflux pumps. Biochem Pharmacol 2000;60:457-70.
64. van de Belt H, Neut D, Schenk W, van Horn JR, et al. Infection of orthopedic implants and the use of antibiotic-loaded bone cements. A review. Acta Orthop Scand 2001;72:557-71.
65. Villani P, Regazzi MB, Marubbi F, Viale P, et al. Cerebrospinal fluid linezolid concentrations in postneurosurgical central nervous system infections. Antimicrob Agents Chemother 2002;46:936-7.
66. von Baum H, Bottcher S, Abel R, Gerner HJ, et al. Tissue and serum concentrations of levofloxacin in orthopaedic patients. Int J Antimicrob Agents 2001;18:335-40.
67. Wagner A, Reike H, Angelkort B. Highly resistant pathogens in patients with diabetic foot syndrome with special reference to methicillin-resistant Staphylococcus aureus infections. Dtsch Med Wochenschr 2001;126:1353-6.
68. Weissberg D, Refaely Y. Pleural empyema: 24-year experience. Ann Thorac Surg 1996;62:1026-9.
69. Wimmer C, Ogon M, Sterzinger W, Landauer F, et al. Conservative treatment of tuberculous spondylitis: a long-term follow-up study. J Spinal Disord 1997;10:417-9.
70. Zeitlinger MA, Dehghanyar P, Mayer BX, Schenk BS, et al. Relevance of soft-tissue penetration by levofloxacin for target site bacterial killing in patients with sepsis. Antimicrob Agents Chemother 2003;47:3548-53.
71. Zeitlinger MA, Marsik C, Georgopoulos A, Muller M, et al. Target site bacterial killing of cefpirome and fosfomycin in critically ill patients. Int J Antimicrob Agents 2003;21:562-7.
72. Zuluaga AF, Galvis W, Jaimes F, Vesga O. Lack of microbiological concordance between bone and non-bone specimens in chronic osteomyelitis: an observational study. BMC Infect Dis 2002;2:8.